本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine. WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval Founded by renowned Dr. Yuquan Wei, Academician of the Chinese Academy of Sciences, and Dr. Xiangrong Song, WestGene has become a driving force in mRNA technology research and innovative drug development. With a relentless pursuit of scientific excellence, WestGene's latest milestone underscores its commitment to advancing the frontiers of biomedicine. The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers. EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus. These are potential indications for WGc-043. WGc-043 shows promising efficacy, low toxicity, broad applicability, efficient scalability, and cost effectiveness. WGc-043 has already completed investigator-initiated trials (IIT) in NPC and NKTL, demonstrating superior safety and efficacy compared to other publicly available mRNA therapeutic cancer vaccines. Once successfully launched, WGc-043 will provide a new treatment option for patients with advanced EB virus-positive solid tumors and hematologic malignancies. As WestGene moves forward, its strategic focus on global collaboration underscores its vision for commercial expansion and market penetration. With a diverse pipeline of over 20 mRNA-based therapeutic products targeting a spectrum of diseases, WestGene is poised to reshape the biopharmaceutical landscape. WestGene has made significant breakthroughs in the three key technologies of mRNA drug development: mRNA sequence design, delivery vectors, and manufacturing. And the patent for ionizable lipids has been granted in countries and regions such as China, the United States and Europe. The FDA approval of WGc-043 marks a turning point in the fight against cancers and underscores WestGene's commitment to mRNA technology. As WestGene continues to push the boundaries of scientific discovery, its pioneering spirit promises to open new frontiers in cancer therapy and beyond.
BEIJING, May 10, 2024 /PRNewswire/ -- A report from People's Daily: China's production capacity is deeply rooted in the country's vast market. China is a developing country with a population of over 1.4 billion. The fundamental purpose of its production is to meet the ever-growing expectation of the people for a better life. Since the reform and opening up, China has transitioned from a planned economy to a socialist market economy, which has boosted production in different sectors and enhanced its supply capabilities. As China's economy continues to grow steadily and with the incremental upgrading of Chinese industries, the potential of China's domestic demand has been consistently expanding and unleashed, which will enhance production capacity in a cycle of mutual reinforcement. China boasts a large and steadily expanding middle-income group, with per capita GDP surpassing $12,000, creating a huge consumer market. In 2023, China's total retail sales of consumer goods exceeded 47 trillion yuan ($6.5 trillion), with final consumption expenditure contributing 82.5 percent to economic growth. Consumption has become the main engine driving economic growth and the primary driver of China's expansion of production capacity. Over the past few years, China has been the world's largest consumer of automobiles, home appliances, clothing, and jewelries, among others. This wouldn't have been possible without massive domestic production capacity, as relying solely on imports wouldn't have been enough. Technological innovation and enhanced production efficiency are the driving forces of China's production capacity. Innovation serves as the engine of productivity. China adopts the innovation-driven development strategy and keeps expanding investment in scientific and technological innovation. It ranks second in the world in terms of total R&D investment. A total of 679 Chinese companies were listed among the world's top 2,500 R&D investors last year. Technological innovation has enhanced China's production efficiency and forged more comparative advantages. In recent years, China's traditional top three products, or the "old three" -- mobile phones, computers and home appliances, and three major tech-intensive green products, or the "new three" -- new energy vehicles (NEVs), lithium-ion batteries and photovoltaic products, have gained widespread popularity in the global market. This success is attributed to the continuous technological innovation and efficiency improvements in the extensive and specialized industries in China, along with the unwavering commitment to excellence by Chinese entrepreneurs. It is particularly important to see that China is the only country in the world that possesses all the industrial categories in the United Nations industrial classification. By harnessing the well-established industrial ecosystem and leveraging market dynamics, China can quickly transform technological innovation achievements into high-quality production capacity. A Bloomberg article said that the global energy transition is largely attributed to China's provision of low-cost and clean products. China is embracing the new round of sci-tech revolution and industrial transformation worldwide and has no intention of criticizing or suppressing other countries that are leading in areas such as artificial intelligence, commercial aerospace, and low-orbit satellites. Instead, China is genuinely committed to learning from others with an aim to promote scientific and technological development through mutual learning and exchanges. Similarly, developed countries should embrace China's technological advancements in areas like new energy with fairness and openness, keeping in mind the benefits of all humanity. A large portion of China's production capacity is attributed to multinationals. Foreign-invested enterprises have played a significant role in the growth of China's manufacturing. As China becomes more integrated into the global economy, many foreign enterprises have chosen China as their primary production base, producing goods for sale on a global scale. Among them are many American companies. For instance, the remarkable success of Apple as the second most profitable and highest-valued company in the world can be largely credited to the dedicated Chinese workers and efficient Chinese enterprises along its supply chain. Apple has announced to expand its R&D labs in China to better support its production line. Tesla produced over 1.84 million new energy vehicles last year, with half of them being manufactured in its Shanghai Gigafactory. Tesla's exports from China account for nearly 30 percent of Chinese exports of the NEVs. Multinationals often follow a typical approach: making decisions at headquarters, manufacturing products in China, distributing them in global markets including China, and repatriating the profits generated to their home countries. Such business model can lead to win-win outcomes for all stakeholders. By launching more important projects in China in the coming future, particularly in industries such as chemistry and the NEVs, multinationals are set to see more improvements in their competitiveness and production capacity. The growth of China's production capacity is credited to the combined efforts of an efficient market and a proactive government. Throughout the history of industrial development in developed countries, successful industrial upgrading relied on both market dynamics and government strategies to guide and support industries. For instance, the rapid economic growth of countries like Japan, Germany, and South Korea after World War II was largely a result of government assistance for key industries. Industrial policies have been a longstanding practice in the United States, with the CHIPS and Science Act alone providing over $52 billion in subsidies. Since the reform and opening up, China has drawn lessons from developed countries and used strong domestic demand to drive economic growth. By directing the allocation of resources through industrial planning, China has been actively developing a modern industrial system. Since the accession to the World Trade Organization, China has consistently complied with the subsidy-related rules and developed its production capacity within a market economy environment. China's industrial policies never violate market principles. China does not seek to exclude competition with other countries or unreasonably favor its own industries. Instead, China aims to continuously improve marketization levels and adopt tailored industrial policies that suit local conditions. This approach allows for orderly competition among industries, ultimately achieving an equilibrium between supply and demand.
SEOUL, South Korea, May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101 was designated as an orphan drug for small cell lung cancer and pancreatic cancer in July of last year and February of this year, respectively. By receiving fast-track designation this time, it is evaluated that it has laid the groundwork that can be commercialized immediately after completion of phase 2 clinical trials. SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer Despite a long period of research and development, SCLC still remains a field with high medical unmet needs. Currently, the first-line standard treatment is a combination therapy of cisplatin and etoposide, a classic cytotoxic anticancer drug, and 'clinical trials' are included as second-line treatments in the NCCN guidelines. Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The Fast Track designation facilitates the interactions with the FDA and allows a rolling review for the submission package so it can be reviewed in each section, rather than waiting until every section of the NDA is completed. Additionally, it may be possible to apply for accelerated approval after the completion of phase 2 clinical trials and priority review immediately after the completion of phase 3 clinical trials when qualified. SNB-101 is the world's first nanoparticle anticancer drug that has been developed extremely insoluble SN-38 into polymer nanoparticles. The nano micelle technology, a core platform technology of SN Bioscience, has been applied. Preclinical and phase 1 clinical results showed that it significantly reduced digestive system adverse events (nausea, vomiting, diarrhea, etc.) compared to existing anticancer drugs, and especially showed excellent efficacy in patients related to lung cancer through lung targeting. The phase 1 clinical trial has been completed, IND for phase 2 has been approved in Korea, and global clinical trials are scheduled to begin after IND approval for phase 2 in the US and Europe in the second half of this year. Following small cell lung cancer and pancreatic cancer, attempts are being made to expand its indications to other solid cancers such as colon cancer, gastric cancer, and biliary tract cancer, and will be verified through phase 2 clinical trials. About SN BioScience Inc. SN BioScience is a biotech company established in May 2017. It is a drug delivery system R&D company specialized in anti-cancer drugs and is located in the 2nd Pangyo Techno Valley in Seongnam-si, Gyeonggi-do, Korea. SN BioScience was founded by pharmaceutical R&D experts, world-class bio-polymer research professors, and clinical professors. From the beginning of its establishment, it has focused on "commercialization" and has been developing nanoliposomes and nanoparticle drug carriers based on pharmacometrics and pharmacokinetics. [SNB-101] The development name, SNB-101, is the world's first anticancer drug developed from SN-38 as nanoparticles. SN-38 is an active metabolite of Irinotecan which is gaining attention for its use in drug-antibody conjugates (ADCs) such as Enhertu® and Trodelvy®. Tolerability and safety have been dramatically improved compared to existing products, and it is expected to be effective in lung cancer, pancreatic cancer, and gastric cancer, were not the indications before. Scale-up production, the biggest barrier that prevented existing nano-cancer drugs from entering the clinical stage, was successful, and clinical trial products are produced at a facility dedicated to anticancer drugs with EU GMP.
HANOI, Vietnam, May 10, 2024 /PRNewswire/ -- Soilbuild Group, an integrated real estate group, has broadened its investment in industrial real estate to Vietnam through its Soilbuild International division. The official launch of Soilbuild International (Vietnam) took place in Hanoi on May 9th, 2024, and was attended by esteemed guests, including domestic and international partners. Delegates at the launching key moment of Soilbuild International Soilbuild has extensive track record of close to 50 years in constructing, developing and managing a diverse portfolio of residential and industrial real estate in Singapore. The launch of Soilbuild International in Vietnam represents a major milestone for Soilbuild as it seeks to leverage on its deep experience in the industrial segment to fulfill the real estate needs of the industrialists in the local market. During the event, Soilbuild unveiled its development plans for ready built factory facilities under the brand, Spectrum, and showcased its first project, Spectrum Nghệ An. The ceremony also featured several upcoming projects planned for development in key economic areas of Northern Vietnam. Spectrum Nghệ An will feature ready built factories ranging from 3.200 sqm to 14.000 sqm, developed in accordance with LEED (Leadership in Energy and Environmental Design) Green Building Standards within the WHA Industrial Zone 2 Nghệ An. Spectrum Nghệ An will cover an area of 15.6 hectares and is scheduled to commence construction in June 2024, with phase 1 expecting to be completed by the first quarter of 2025. During the event, Ms Anchalee Prasertchand, Vice President of WHA, a leading developer of Industrial Estates and Industrial Parks presented the Land Use Certificate to Soilbuild, establishing a solid foundation for long-term cooperation between the entities. In his statement at the launch event, Mr. Ding Khoon Yew, General Director of Soilbuild International (Vietnam), stated, "Vietnam is a country benefiting greatly from the global supply chain shift. With the participation of major multinational corporations, there is a growing demand for quality ready built factories and warehouses aligned with global standards. Soilbuild is committed to build upon the foundation that we have accrued over the years to develop quality industrial space catering to the diverse needs of the local and multinational corporation and to support them through their business growth." Soilbuild also signed a strategic partnership agreement with GreenA Consultants, a well-established Sustainability Consultancy firm, to co-develop sustainability framework and advisory for the Soilbuild's industrial developments in Vietnam. This signifies Soilbuild's commitment to promoting green and sustainable standards in Vietnam's industrial real estate sector. Mr Lim Han Qin, Director of Soilbuild said, "Soilbuild has been an early adopter of sustainability with our very first building achieving the highest green mark standard in Singapore since 2010. Through the years, we have been pushing the boundary of our sustainability journey to not only reduce the overall energy consumption and emissions, but also to secure a more sustainable future and resilient urban landscape for future generations." About Soilbuild Group Holdings Ltd. Soilbuild is a leading integrated property group with an established track record of constructing, developing and managing an award-winning portfolio of residential and business space properties. With over 47 years of experience, Soilbuild has developed a range of residential properties from high-end luxury condominiums to landed and conservation houses. Soilbuild has also developed a multitude of functional business spaces catering to the needs of multinational corporations and local enterprises in various sectors and received top honors as the Best Industrial Developer during the PropertyGuru Asia Property Awards 2020. The Group's business space portfolio includes flagship developments in Solaris @ one-north, Solaris @ Kallang164, Tai Seng Exchange, Trion, Revv, West Park Biz Central and Eightrium @ Changi Business Park. Soilbuild's focus on sustainability and quality has also been recognized through the Green Mark Platinum accreditation (Singapore Green Building Standard) for its various projects, and awards including the World Gold Winner in the sustainable development category for Solaris @ one-north at the prestigious FIABCI World Prix d'Excellence Awards 2016, Skyrise Greenery Awards held by Singapore Institute of Architects and National Parks Singapore, the Green Good Design Award for Architecture from the Chicago Athenaeum for Solaris @ one-north, as well as the Best Industrial Smart Building Development for Tai Seng Exchange.
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 10 May 2024 - ZF Aftermarket, renowned for its comprehensive systems solutions, unveiled a series of innovation poised to raise the benchmark for the commercial vehicle industry. With its strong legacy in e-mobility and digitalization, ZF Aftermarket launched a much-anticipated suite of products, meticulously developed to meet the stringent requirements of commercial vehicles. "Our latest suite of products underscores our proactive approach towards the evolving demands of the commercial vehicle industry. We have harnessed our global expertise to engineer solutions that are uniquely tailored to meet the Southeast Asia market's specific climatic and operational challenges. This initiative marks our range as not only responsive to current industry demands but a step ahead, anticipating and shaping the trajectory of future mobility," said Chee How Teoh, Head of Aftermarket Asia Pacific at ZF Aftermarket. SACHS, Innovative Clutch Systems Integrating German precision with local market insights, the latest clutch systems raise the bar for operational efficiency with extended replacement intervals reaching 700,000km, reflecting ZF Aftermarket's commitment to enhanced efficiency, precision, and lasting performance. SACHS, Advanced Shock Absorbers A further leap was made in vehicular stability and safety with the new shock absorbers, which not only improve tire lifespan but also reduce tire wear caused by shock absorber degrading. By reducing braking distances and tire wear, they not only bolster driver safety but underscore ZF Aftermarket's dedication to solutions that improve not just vehicle performance, but also contribute to cost-effectiveness. High-Performing Transmission Fluids ZF Aftermarket completed its trio of innovations by introducing high-performing Non ZF - transmission fluids specifically tailored for all types of commercial vehicles, including both mechanical and automatic transmissions. This product is a result of extensive research to enhance performance and longevity, specifically within the demanding SOUTHEAST ASIA climate and road conditions. "Our innovations attest to ZF Aftermarket's leadership in technology and strategic foresight. They empower our customers to lead their markets with commercial vehicles that boast reliability, efficiency and a design tailored to the SOUTHEAST ASIA region's demanding climate and terrain," said Aleksander Rabinovitch, Head of Business Line Commercial Vehicles at ZF Aftermarket. As the region's commercial transport sector flourishes, ZF Aftermarket showcased its comprehensive commitment to increasing uptime, reliability, and efficiency – critical aspects for public transport operators, logistics companies, and fleet owners. As such, its products are designed to deliver performance while minimising maintenance and downtime, crucial for the SOUTHEAST ASIA region's burgeoning commercial transportation sector. Further underlining its global expertise with a local touch, ZF Aftermarket showcased its ZF [pro] Service workshop concept, a service programme designed for commercial vehicles that integrates three key concepts into a single, cohesive service solution. This programme offers a full spectrum of advantages to partners, including technical training, special tooling conditions, and marketing support. For further details on ZF Aftermarket's innovative solutions, please visit aftermarket.zf.com. Hashtag: #ZFAftermarketThe issuer is solely responsible for the content of this announcement.
BEIJING, May 10, 2024 /PRNewswire/ -- On May 4, the 18th Beijing International Automotive Exhibition concluded successfully. At this auto show, GWM fully demonstrated the brand's "long-termism" development strategy, innovative technological achievements and rich development potential. At this auto show, GWM demonstrated the brand's continuous deepening in the process of global development. Dozens of products from the brand's five major product lines gathered at the auto show, including GWM TANK 700 Hi4-T, GWM WEY 80 Intelligent Edition, all-new GWM HAVAL H9, 2024 GWM ORA 03, etc., demonstrating the brand's rich product mix and powerful driving performance, and attracting thousands of global guests to explore and place orders on site. Global partners and media came to the GWM headquarters to visit the brand's R&D center to gain an in-depth understanding of the brand's decades of accumulation in new energy power technology and vehicle manufacturing technology. GWM has been insisting on taking practical measures to promote ecological globalization and achieve global development. At present, the brand has established R&D centers in seven countries and ten places around the world, established full-vehicle overseas production plants in Thailand and Brazil, and multiple KD production plants around the world to meet global localized production needs and provide products that adapt to local environments and needs. Apart from providing a large number of jobs, GMW has also built a complete new energy supply chain system locally, such as the construction of the SVOLT Energy factory in Thailand, injecting new impetus into global industrial development. Through long-term global development, GWM's ecological globalization development has entered the harvest period. With the proposal of the ONE GWM strategy, GWM continues to make efforts to develop global markets in-depth and achieve "localization with roots overseas" development. From March to April, GWM TANK series products were launched in global markets such as Australia, South Africa, and Indonesia, and received high praise from owners. The main products sold have received ANCAP and Euro-NCAP five-star ratings, demonstrating excellent market competitiveness. GWM implements the ecological overseas strategy to promote the improvement of the entire link of research, production, supply, sales and service globally. At the GWM International Press Conference, the brand demonstrated the continuous deepening of GWM Care services, meeting the full-process needs of consumers for car usage. The brand also plans to cooperate with the modification ecological partners and carries out the GWM Life Program, constantly enriching owners' driving experience and feelings, and shaping a global brand and product culture. GWM has been deeply rooted in the global market for 27 years, leading the brand's global development with long-termism and achieving outstanding achievements. In the future, GWM will continue to promote brand globalization with stable and high-quality development and build an intelligent brand with a global vision.
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
